JP2010528035A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010528035A5 JP2010528035A5 JP2010509512A JP2010509512A JP2010528035A5 JP 2010528035 A5 JP2010528035 A5 JP 2010528035A5 JP 2010509512 A JP2010509512 A JP 2010509512A JP 2010509512 A JP2010509512 A JP 2010509512A JP 2010528035 A5 JP2010528035 A5 JP 2010528035A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pain
- independently
- compound
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 86
- -1 —OH Chemical group 0.000 claims description 82
- 208000002193 Pain Diseases 0.000 claims description 69
- 125000001931 aliphatic group Chemical group 0.000 claims description 44
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 239000001257 hydrogen Substances 0.000 claims description 44
- 125000005843 halogen group Chemical group 0.000 claims description 34
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- 150000002431 hydrogen Chemical class 0.000 claims description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 230000001154 acute effect Effects 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 125000003107 substituted aryl group Chemical group 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 230000001684 chronic effect Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 208000004296 neuralgia Diseases 0.000 claims description 12
- 125000004043 oxo group Chemical group O=* 0.000 claims description 12
- 208000008035 Back Pain Diseases 0.000 claims description 11
- 125000002723 alicyclic group Chemical group 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 208000005298 acute pain Diseases 0.000 claims description 10
- 208000021722 neuropathic pain Diseases 0.000 claims description 10
- 230000002981 neuropathic effect Effects 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 206010019233 Headaches Diseases 0.000 claims description 6
- 208000019695 Migraine disease Diseases 0.000 claims description 6
- 206010028836 Neck pain Diseases 0.000 claims description 6
- 208000004550 Postoperative Pain Diseases 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 206010027599 migraine Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 208000009935 visceral pain Diseases 0.000 claims description 6
- 208000008930 Low Back Pain Diseases 0.000 claims description 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 208000000003 Breakthrough pain Diseases 0.000 claims description 4
- 206010058019 Cancer Pain Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 208000006561 Cluster Headache Diseases 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 208000007514 Herpes zoster Diseases 0.000 claims description 4
- 206010065390 Inflammatory pain Diseases 0.000 claims description 4
- 208000004404 Intractable Pain Diseases 0.000 claims description 4
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 4
- 208000008765 Sciatica Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 4
- 108010052164 Sodium Channels Proteins 0.000 claims description 3
- 102000018674 Sodium Channels Human genes 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 208000004998 Abdominal Pain Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010003011 Appendicitis Diseases 0.000 claims description 2
- 208000006820 Arthralgia Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010006002 Bone pain Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 206010064012 Central pain syndrome Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 206010008479 Chest Pain Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- 206010016059 Facial pain Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 2
- 206010021639 Incontinence Diseases 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- 208000007914 Labor Pain Diseases 0.000 claims description 2
- 208000035945 Labour pain Diseases 0.000 claims description 2
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 2
- 208000005890 Neuroma Diseases 0.000 claims description 2
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 208000000450 Pelvic Pain Diseases 0.000 claims description 2
- 208000010886 Peripheral nerve injury Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 206010037596 Pyelonephritis Diseases 0.000 claims description 2
- 206010038419 Renal colic Diseases 0.000 claims description 2
- 206010040037 Sensory neuropathy hereditary Diseases 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 206010043269 Tension headache Diseases 0.000 claims description 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 210000001015 abdomen Anatomy 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 150000007824 aliphatic compounds Chemical class 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 208000034757 axonal type 2FF Charcot-Marie-Tooth disease Diseases 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 210000003414 extremity Anatomy 0.000 claims description 2
- 238000010304 firing Methods 0.000 claims description 2
- 230000005176 gastrointestinal motility Effects 0.000 claims description 2
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 claims description 2
- 201000006847 hereditary sensory neuropathy Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 230000003340 mental effect Effects 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 208000015706 neuroendocrine disease Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 208000020629 overactive bladder Diseases 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000001297 phlebitis Diseases 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 208000005198 spinal stenosis Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 210000003371 toe Anatomy 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N benzocyclopentane Natural products C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims 2
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 206010033557 Palpitations Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 201000000182 femoral cancer Diseases 0.000 claims 1
- 210000002414 leg Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 125000004957 naphthylene group Chemical group 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 0 CC(*)(C(*=C)(*=C)I(C)*)NC Chemical compound CC(*)(C(*=C)(*=C)I(C)*)NC 0.000 description 29
- 238000000034 method Methods 0.000 description 6
- FUKPTAWOWUTIBA-UHFFFAOYSA-N CC(C(SC)=O)[n](cc1)c2c1c(F)cc(F)c2 Chemical compound CC(C(SC)=O)[n](cc1)c2c1c(F)cc(F)c2 FUKPTAWOWUTIBA-UHFFFAOYSA-N 0.000 description 1
- GDPJRYCXJJQWRN-UHFFFAOYSA-N CC(C[n](cc1)c2c1ccc(OC)c2)=O Chemical compound CC(C[n](cc1)c2c1ccc(OC)c2)=O GDPJRYCXJJQWRN-UHFFFAOYSA-N 0.000 description 1
- JCJVMJJPCWFFTR-UHFFFAOYSA-N CC(C[n]1c2cccc(F)c2cc1)=O Chemical compound CC(C[n]1c2cccc(F)c2cc1)=O JCJVMJJPCWFFTR-UHFFFAOYSA-N 0.000 description 1
- NXHFMBXQSRGPRD-UHFFFAOYSA-N Cc1c(cc[n]2CC=C)c2ccc1 Chemical compound Cc1c(cc[n]2CC=C)c2ccc1 NXHFMBXQSRGPRD-UHFFFAOYSA-N 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000664 voltage gated sodium channel blocking agent Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93172207P | 2007-05-25 | 2007-05-25 | |
| PCT/US2008/064314 WO2008147797A2 (en) | 2007-05-25 | 2008-05-21 | Ion channel modulators and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010528035A JP2010528035A (ja) | 2010-08-19 |
| JP2010528035A5 true JP2010528035A5 (enExample) | 2012-06-07 |
Family
ID=39876632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010509512A Pending JP2010528035A (ja) | 2007-05-25 | 2008-05-21 | イオンチャネル調節物質およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8193194B2 (enExample) |
| EP (1) | EP2158183A2 (enExample) |
| JP (1) | JP2010528035A (enExample) |
| CN (1) | CN101687782A (enExample) |
| AU (1) | AU2008256937A1 (enExample) |
| CA (1) | CA2687764A1 (enExample) |
| MX (1) | MX2009012678A (enExample) |
| NZ (1) | NZ581309A (enExample) |
| WO (1) | WO2008147797A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| ZA200802977B (en) * | 2005-09-09 | 2009-08-26 | Vertex Pharma | Bicyclic derivatives as modulators of voltage gated ion channels |
| EP1948597A1 (en) * | 2005-10-21 | 2008-07-30 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
| CA2687764A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| CN102036985A (zh) | 2007-11-13 | 2011-04-27 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的作为离子通道调节剂的4(-3-(-2-(苯基)吗啉代)-2-氧代吡咯烷-1-基)-n-(噻唑-2-基)苯磺酰胺衍生物和相关化合物 |
| AU2008321142A1 (en) * | 2007-11-13 | 2009-05-22 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| US20110031892A1 (en) * | 2008-04-30 | 2011-02-10 | Sharp Kabushiki Kaisha | Lighting device and display device |
| DK2616465T3 (da) * | 2010-09-13 | 2016-02-01 | Novartis Ag | Triazin-oxadiazoler |
| WO2012095781A1 (en) * | 2011-01-13 | 2012-07-19 | Pfizer Limited | Indazole derivatives as sodium channel inhibitors |
| ES2586213T3 (es) | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| MX2014005304A (es) | 2011-10-31 | 2015-03-20 | Xenon Pharmaceuticals Inc | Biaril eter sulfonamidas y su uso como agentes terapeuticos. |
| CA2874621A1 (en) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
| US10071957B2 (en) | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| CN105026373B (zh) | 2013-01-31 | 2018-03-30 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的吡啶酮酰胺 |
| CN105263490B (zh) | 2013-03-14 | 2018-05-22 | 基因泰克公司 | 取代的三唑并吡啶及其使用方法 |
| CA2898680A1 (en) | 2013-03-15 | 2014-09-18 | Genentech,Inc. | Substituted benzoxazoles and methods of use thereof |
| JP6383418B2 (ja) | 2013-11-27 | 2018-08-29 | ジェネンテック， インコーポレイテッド | 置換ベンズアミド及びその使用方法 |
| EP2878339A1 (en) | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
| CN106715418A (zh) | 2014-07-07 | 2017-05-24 | 基因泰克公司 | 治疗化合物及其使用方法 |
| KR102364840B1 (ko) | 2014-11-05 | 2022-02-18 | 삼성전자주식회사 | 신경세포의 탈수초화와 연관된 질환을 치료하기 위한 약학적 조성물 및 그를 이용하는 방법 |
| MA42118A (fr) | 2015-05-22 | 2018-03-28 | Genentech Inc | Benzamides substitués et leurs méthodes d'utilisation |
| US9771335B2 (en) * | 2015-07-31 | 2017-09-26 | The Johns Hopkins University | Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels |
| WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| JP6987746B2 (ja) | 2015-09-28 | 2022-01-05 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| TW201718557A (zh) * | 2015-10-08 | 2017-06-01 | 歌林達有限公司 | 經吡唑基取代之四氫吡喃基碸 |
| TW201726128A (zh) * | 2015-10-08 | 2017-08-01 | 歌林達有限公司 | 經吡唑基取代之四氫哌喃基碸 |
| US10899732B2 (en) | 2015-11-25 | 2021-01-26 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| PT3426243T (pt) | 2016-03-09 | 2021-08-19 | Raze Therapeutics Inc | Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos |
| EP4234552A3 (en) * | 2016-03-09 | 2023-10-18 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
| US10766858B2 (en) | 2016-03-30 | 2020-09-08 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| RU2638784C1 (ru) * | 2016-09-14 | 2017-12-15 | Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз" | Способ лечения миофасциальных болей в мышцах шеи по Гурову-Левину |
| BR112019007763A2 (pt) | 2016-10-17 | 2019-07-02 | Genentech Inc | composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção |
| EP3601273B1 (en) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| WO2019191702A1 (en) | 2018-03-30 | 2019-10-03 | F. Hoffmann-La Roche Ag | Substituted hydro-pyrido-azines as sodium channel inhibitors |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| WO2024158872A1 (en) * | 2023-01-25 | 2024-08-02 | The Rockefeller University | 1,3-indole-propanamide inhibitors of sars-cov-2 plpro/nsp3 and derivatives thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD9688A (enExample) * | ||||
| US2411495A (en) * | 1938-02-02 | 1946-11-19 | Schering Corp | Valuable derivatives of sulphonamides and a method of making the same |
| DE840241C (de) * | 1938-02-03 | 1952-05-29 | Schering Ag | Verfahren zur Herstellung von Abkoemmlingen von Sulfonamiden |
| GB598472A (en) * | 1943-11-05 | 1948-02-19 | Geigy Ag J R | Manufacture of para-aminobenzene sulphonacylamides |
| GB604259A (en) * | 1944-12-28 | 1948-06-30 | Geigy Ag J R | Manufacture of 4-aminobenzenesulphonyl-ureas |
| US2907692A (en) * | 1953-02-11 | 1959-10-06 | Boehringer & Soehne Gmbh | Composition for treating diabetes and a process of administering same |
| US3065225A (en) * | 1960-02-05 | 1962-11-20 | Hoffmann La Roche | N', n4-di-isoxazolylcarbonyl-sulfanilamide derivatives |
| CH435298A (fr) * | 1963-10-08 | 1967-05-15 | Gevaert Photo Prod Nv | Procédé de préparation de 3-acylamino-5-pyrazolones |
| BE666204A (enExample) * | 1964-06-30 | |||
| CH459222A (de) * | 1965-10-27 | 1968-07-15 | Sandoz Ag | Verfahren zur Herstellung von neuen heterocyclischen Sulfonylharnstoff-Derivaten |
| RO62697A2 (fr) * | 1974-05-04 | 1978-03-15 | Sintofarm Intreprinderea | Derives du 2,3-dihydro-1,3-benzoxazine-2,4-dione et procede de preparation |
| JPS6055062B2 (ja) * | 1979-09-21 | 1985-12-03 | 塩野義製薬株式会社 | Ｎ↑４−フエノキシアセチルスルフアニルアミド類および除草剤 |
| US4461773A (en) * | 1982-09-15 | 1984-07-24 | E. I. Dupont De Nemours And Company | P-Oxooxazolidinylbenzene compounds as antibacterial agents |
| EP0116518B1 (de) | 1983-02-04 | 1987-10-28 | Ciba-Geigy Ag | N-Phenylsulfonyl-N'-pyrimidinyl- und -triazinylharnstoffe |
| ES2054088T3 (es) * | 1988-10-20 | 1994-08-01 | Ciba Geigy Ag | Sulfamoilfenilureas. |
| TW352384B (en) * | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
| JPH06135940A (ja) * | 1992-10-22 | 1994-05-17 | Mitsubishi Petrochem Co Ltd | 新規なハロゲン化スルホンアミド誘導体およびそれを有効成分とする除草剤 |
| CA2110524A1 (en) * | 1992-12-10 | 1994-06-11 | Gerald Burr Grindey | Antitumor compositions and methods of treatment |
| US5620997A (en) * | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| DE19621522A1 (de) * | 1996-05-29 | 1997-12-04 | Hoechst Schering Agrevo Gmbh | Neue N-Acylsulfonamide, neue Mischungen aus Herbiziden und Antidots und deren Verwendung |
| JP3050126B2 (ja) * | 1996-06-11 | 2000-06-12 | 日本製紙株式会社 | 感熱記録体 |
| JP2000198272A (ja) * | 1998-11-04 | 2000-07-18 | Oji Paper Co Ltd | 可逆性感熱記録体 |
| EP1392643B1 (en) * | 2001-05-18 | 2005-09-14 | Abbott Laboratories | Trisubstituted-n- (1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors |
| MXPA04001253A (es) * | 2001-08-09 | 2004-06-03 | Ono Pharmaceutical Co | Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo. |
| RS63204A (sr) * | 2002-01-17 | 2006-10-27 | Neurogen Corporation | Supstituisani analozi hinazolin-4-ilamina kao modulatori kapsaicina |
| JP2003321460A (ja) * | 2002-02-28 | 2003-11-11 | Takeda Chem Ind Ltd | アゾール化合物 |
| EP1663994B1 (en) * | 2003-08-05 | 2012-03-07 | Vertex Pharmaceuticals Incorporated | Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels |
| KR20060073930A (ko) * | 2003-08-08 | 2006-06-29 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체 |
| US7615563B2 (en) | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| BRPI0507278A (pt) | 2004-01-30 | 2007-06-26 | Vertex Pharma | moduladores dos transportadores do cassete de ligação ao atp |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| ES2257929B1 (es) * | 2004-07-16 | 2007-05-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos. |
| DE102004035132A1 (de) | 2004-07-20 | 2006-02-16 | Bayer Cropscience Ag | Insektizide Mittel auf Basis von ausgewählten Insektiziden und Safenern |
| EA200701324A1 (ru) * | 2004-12-23 | 2007-10-26 | Глэксо Груп Лимитед | Соединения пиридина для лечения заболеваний, опосредованных действием простагландина |
| CN101218235A (zh) | 2005-05-10 | 2008-07-09 | 沃泰克斯药物股份有限公司 | 作为离子通道调控剂的二环衍生物 |
| EP1888558B1 (en) | 2005-05-16 | 2011-10-05 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of ion channels |
| EP1891039A1 (en) | 2005-05-20 | 2008-02-27 | Vertex Pharmaceuticals Incorporated | Quinoline derivatives useful as modulators of ion channels |
| WO2006133459A1 (en) | 2005-06-09 | 2006-12-14 | Vertex Pharmaceuticals Incorporated | Indane derivatives as modulators of ion channels |
| ZA200802977B (en) | 2005-09-09 | 2009-08-26 | Vertex Pharma | Bicyclic derivatives as modulators of voltage gated ion channels |
| US7683083B2 (en) | 2005-10-12 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
| EP1948597A1 (en) | 2005-10-21 | 2008-07-30 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
| PT2404919E (pt) | 2005-11-08 | 2013-10-22 | Vertex Pharma | Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp |
| WO2007075895A2 (en) | 2005-12-21 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| EP2016065B1 (en) | 2005-12-28 | 2012-09-19 | Vertex Pharmaceuticals Incorporated | 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| JP5420395B2 (ja) | 2006-04-07 | 2014-02-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｐ結合カセット輸送体の調節剤 |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| CA2687764A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| US7994174B2 (en) | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| AU2008321142A1 (en) | 2007-11-13 | 2009-05-22 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| CN102036985A (zh) | 2007-11-13 | 2011-04-27 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的作为离子通道调节剂的4(-3-(-2-(苯基)吗啉代)-2-氧代吡咯烷-1-基)-n-(噻唑-2-基)苯磺酰胺衍生物和相关化合物 |
| CN102743385B (zh) | 2007-11-16 | 2014-09-17 | 沃泰克斯药物股份有限公司 | Atp结合盒转运蛋白的异喹啉调节剂 |
| HUE049642T2 (hu) | 2007-12-07 | 2020-09-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái |
| CA2989620C (en) | 2007-12-07 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| CA2716109C (en) | 2008-02-28 | 2016-07-19 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
| NZ616097A (en) | 2008-03-31 | 2015-04-24 | Vertex Pharma | Pyridyl derivatives as cftr modulators |
| EP2307412A2 (en) | 2008-07-01 | 2011-04-13 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| WO2010037066A2 (en) | 2008-09-29 | 2010-04-01 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
-
2008
- 2008-05-21 CA CA002687764A patent/CA2687764A1/en not_active Abandoned
- 2008-05-21 JP JP2010509512A patent/JP2010528035A/ja active Pending
- 2008-05-21 AU AU2008256937A patent/AU2008256937A1/en not_active Abandoned
- 2008-05-21 EP EP08769547A patent/EP2158183A2/en not_active Withdrawn
- 2008-05-21 CN CN200880021348A patent/CN101687782A/zh active Pending
- 2008-05-21 NZ NZ581309A patent/NZ581309A/en not_active IP Right Cessation
- 2008-05-21 US US12/124,303 patent/US8193194B2/en active Active
- 2008-05-21 MX MX2009012678A patent/MX2009012678A/es not_active Application Discontinuation
- 2008-05-21 WO PCT/US2008/064314 patent/WO2008147797A2/en not_active Ceased
-
2012
- 2012-04-27 US US13/457,855 patent/US8883766B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526919A5 (enExample) | ||
| RU2011103451A (ru) | Гетероциклические производные в качестве модуляторов ионных каналов | |
| JP2014508756A5 (enExample) | ||
| JP2011503112A5 (enExample) | ||
| JP2010539244A5 (enExample) | ||
| RU2010123781A (ru) | Производные 4-(2-фенил)-морфолино)-2-оксопирролидин-1-ил)-n-(тиазол-2-ил)бензолсульфонамида и родственные соединения в качестве модуляторов ионных каналов для лечения боли | |
| JP2011503191A5 (enExample) | ||
| AU2019356565B2 (en) | Prodrug modulators of the integrated stress pathway | |
| RU2016104080A (ru) | Амиды конденсированного пиперидина в качестве модуляторов ионных каналов | |
| RU2397976C2 (ru) | Производные бензамидов и гетероаренов | |
| JP2011500598A5 (enExample) | ||
| CN100369894C (zh) | 氧化氮合酶抑制剂磷酸盐 | |
| RU2009100159A (ru) | Тиенопирамидины, полезные в качестве модуляторов ионных каналов | |
| RU2010123876A (ru) | Гетероциклические производные в качестве модуляторов ионных каналов | |
| JP2014504642A5 (enExample) | ||
| CN1280266C (zh) | 酰基苯基脲衍生物,其制备方法和作为药物的用途 | |
| JP2014508169A5 (enExample) | ||
| JP2013502431A5 (enExample) | ||
| JP2013502430A5 (enExample) | ||
| RU2011106948A (ru) | Новые производные оксима холест-4-ен-3-она, фармацевтические композиции, их содержащие, и способ получения | |
| BRPI0817864A2 (pt) | uso de um composto derivado de ceramida | |
| JP2013542929A5 (enExample) | ||
| JP2010505865A5 (enExample) | ||
| JP2022537140A5 (enExample) | ||
| JP2023541203A5 (enExample) |